Michel Ducreux, ESMO 2019 - Treating advanced pancreatic cancer скачать в хорошем качестве

Michel Ducreux, ESMO 2019 - Treating advanced pancreatic cancer

We joined Michel Ducreux (Gustave Roussy Cancer Campus) at ESMO 2019 to discuss the challenges and recent advances in treating pancreatic cancer. Questions 1. What are the major challenges in the treatment of advanced pancreatic cancer? (00:04) 2. Why is it important to treat advanced pancreatic cancer faster? (00:30) 3. What have been the most important recent clinical advances in the treatment of advanced pancreatic cancer? (01:06) 4. What advances have been made in the development of biomarkers to inform treatment decisions? (01:56) 5. How important is genetic testing to personalise therapy in pancreatic cancer? (02:39) Michel Ducreux has participated in advisory boards for Roche, Merck Serono, Amgen, Novartis, Sanofi, Bayer, Lilly, Servier, Ipsen, MSD. He has acted as a symposium speaker for Roche, Merck Serono, Novartis, Ipsen, Lilly, Amgen and Bayer. He has received research funding from Roche, Merck Serono and Keocyt; and has an immediate family member who has other relationships with Sandoz. Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain. touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.